Vitamin K 1 (Vit K 1 )Oral Vit K

1/2 oz
$30.00

2--1/2 oz bottles
$54.00

3-1/2 oz
$75.00

6-1/2 oz
$133.00

12-1/2 oz
$235.00

Vitamin K 1 (Vit K 1 )Oral Vit K
Please do not use PAYPAL to pay for this as it slows down delivery to the extreme and most of you are ordering at the last minute.

This is the only oral vit K available in the US.

NOTICE
Ingrediants and size has changed
Natural Vit K

Priority Mail shipping is included in the pricing-it is 2-3 days. If you do want it quicker, make a note on the last page of the order form. If you are out of the USA I can not promise when it will get there as Customs in your country is very uncertain, there is NO refund for international shipments.

Returns will not be taken as it is a dated product. Do not buy this product unless absolutely sure you want to use it.

Go to the Midwives Archives for all kinds of info on the use of this product.
http://www.gentlebirth.org/archives/vitktop.html
I also have a downloadable file of information that for $10 I will send to you
K-Quinone-(Scientific Botanicals, Inc) is an oil soluble source of vitamin K-1 (phytonadione), the non-toxic natural form of vitamin K present in plants.
K-Quinoe is extracted from alfalfa, nettles and green tea. It is now in a base for Olive Extract and Soy Extract..

Each drop provides 2 mg of vitamin K-1 activity.
The bottle is now 1/2 oz size and contains 440 doses put they have a longer shelf life. It appears that it is 6 months now.

ACTIONS: vitamin K-1 is necessary for changing glutamic acid to gamma carboxy galutamic acid, which is specifically capable of binding calcium ions. These changes take place in various sites such as: (Kidney proteins-which inhibit formation of calcium oxalate stones, Osteocalcin-which is needed for repair and remodeling of bones, and Clotting factors II, VII, IX, and X. (1,2,3))
Vitamin K-1 administered several days before birth has beneficial effects on the relative prothrombin deficiency commonly seen in neonates. When given orally to nursing mothers vitamin K-1 is easily passed through the breast milk to the infant and can reduce the risk of hypoprothrombenemia in breast fed infants. (7)
*Proteins C and S which have fibrinolytic and anticoagulant activities are also vitamin K-1 dependent. (4)
*Vitamin K-1 has demonstrated anti-inflammatory activity by decreasing the complement cascade, and also by potentiating the anti-inflammatory effects of steroids. (5,6)
* Vitamin K-1 has demonstrated an analgesic effect nearly as effective as that of morphine and barbiturates when injected in patients with inoperable carcinomas. (8)
USES; VITAMAN k Supplement: K-Quinone provides a natural and non-toxic source of vitamin K-1, as opposed to menadione, the water soluble form, and may be prescribed for patients in whom a vitamin K-1 deficiency is suspected. A wide range of medications have been shown to reduce vitamin K-1 levels including anticonvulsants, analgesics, antibiotics, and anticoagulants. Patients taking any of these medications may develop disorders of clotting or calcium metabolism indicating the need for supplemental K-Quinone. Calcium Dysmetabolism:
Additional vitamin K-1 is indicated for patients with kidney stones, osteoporosis, fractures, or other disorders of calcium metabolism. Clotting Disorders: Hypoprothrombenemia or the presence of these bleeding disorders would be an indication for additional Vitamin K. Vitamin K may be indicated in clotting disorders as well as bleeding problems because several fibrinolytic proteins are vitamin K dependant. Thus vitamin K may be thought of as having as alternative effect on the clotting cascade.
Anti-Inflammatory: K-Quinone may be utilized in situations where one wishes to potentiate the anti-inflammatory, antigranulomatous activity of steroids. This could be combined with Lick-Rich and Ananacur to further reduce the need for exogenous steroids while maintaining similar therapeutic results without side effects.
Dosage: Up to ten drops twice daily with meals for adults.
References:
1. J. Biol. Chem 1981: 256;3936 Purification and isolation of a calcium oxalate monohydrate crystal growth inhibitor from human kidney tissue culture medium.
2. Nut. Rev. 1979:37;54 Osteocalcin: A Vitamin K dependent calcium binding protein in bone.
3. Lancet Aug. 4, 1984 p. 283 circulating Vitamin K-1 levels in fractured neck of femur.
4. N.E.J.M. 1984: 310; 1458 vitamin K dependent proteins.
5. Arch. Of Pharmacol. 1979: 307;185 Anti-inflammatory effect of warfarin and vitamin K-1.
6. Endocrinology 1965: 76;780 Antigranulomatous activity of vitamin K-1 and its summation with that of prednisolone.
7. Amer. J. Dis. Children 1942: 64;462 Percutaneous absorption of Vitamin K.
8. P.S.E.B.M. 1955: 90; 660 Analgesic property of Vitamin K-12

drops p o = 4 mgs Vit K
From the Midwives Archives

Vitamin K Protocols
1 drop at birth, 1 drop at 1 week and 1 month
From Nursing Times, October 14, 1998: Researchers have found that plasma vitamin K concentrations were at least equal to or significantly higher in babies who are given the new oral form compared to those who are given the vitamin via injection. The oral form is given in doses of 2 mg soon after birth and again four to seven days later. It has been recommended that if the baby is being breastfed, an additional dose be given when it is one month old. I have mom take oral Vit. K for two weeks prior to EDD. I find this helps bleeding pp as well. Then I give baby 2 drops at birth (before I leave) and then again on day five. ---------------------------------------------------------------------------------------------------- I am curious why you give 2 drops of vitamin K. I was thinking that I would need to give them the same amount of mgs as I would of the synthetic. Do you know more about this, any study on this, or suggested amount. When I worked at a birth center they gave the injectable orally, and it was 50mg. Just wondering what you think about giving the natural vit. K in the same dose. I give the same dose PO as is suggested for IM. Some, I have heard, do double the dose when giving it PO. we give three doses, following one of the european protocols (birth, one week, three weeks). Not certain whether this is needed or not, but what the heck... perhaps is does extend protection and lessen the low incidence of late onset hemorrhagic disease. The dose is two drops. How does it taste? I have tasted it! One brand (aquamephytin) tasted rather fishy -- not gawdawful, just not my favorite flavor! babies seem to get down the two drops without flinching. the brand we have been using for a while is alphalpha-derived (I hear) and does not have much taste at all. How to Administer Vitamin K Orally
I have seen Vitamin K administered orally as follows:
The Vitamin K is drawn up as if for the injection, although you draw up a double dose for oral administration. Once the fluid is in the syringe, you remove the needle. Then you help the baby to be as comfortable as possible, insert the syringe into the side of the babys mouth so the tip is kind of in the back corner behind the taste buds. Then you slowly push the plunger to push the fluids into the babys mouth. If done slowly and gently, this does not seem to bother them.

Oral Vitamin K Comparable to IV for Patients With Excessive Anticoagulation
News Author: Laurie Barclay, MD
CME Author: Charles Vega, MD
Authors and Disclosures
Nov. 12, 2003 — Oral vitamin K (phytonadione) is as safe and effective as intravenous vitamin K for patients with excessive anticoagulation, according to the results of a prospective, randomized trial published in the Nov. 10 issue of the Archives of Internal Medicine.
Concerns have been raised regarding possible adverse effects of intravenous phytonadione therapy, such as thrombosis or anaphylaxis, write Aharon Lubetsky, MD, and colleagues from Tel Aviv University in Israel. Oral administration of phytonadione has been shown to be an effective alternative to the intravenous route, but these methods have never been compared directly.
Consecutive patients presenting with excessive anticoagulation without major bleeding received 0.5 mg intravenous phytonadione or 2.5 mg oral phytonadione if their baseline international normalized ratio (INR) was 6 to 10 (47 episodes in 44 patients), and they received 1 mg intravenous phytonadione or 5 mg oral phytonadione if their INR was greater than 10 (19 episodes in 17 patients).
In patients with baseline INR levels of 6 to 10, the response was more rapid to intravenous than to oral phytonadione, and a greater proportion of patients in the intravenous group achieved an INR level in therapeutic range at six hours (11 of 24 patients vs. 0 of 23 patients) and at 12 hours (16 of 24 patients vs. 8 of 23 patients). At 24 hours, mean INR values were similar in both groups. Overcorrection (INR less than 2) occurred more frequently in the intravenous group (7 of 24 patients vs. 2 of 23 patients).
In patients with baseline INR levels greater than 10, both routes of administration offered comparable efficacy and safety.
Patients with excessive anticoagulation should receive treatment according to their INR at presentation, the authors write. When restoration of INR is not considered urgent, oral phytonadione is the better alternative compared with intravenous phytonadione. Since response to oral phytonadione is predictable, it may also be possible to administer phytonadione at home and avoid unnecessary hospitalization.
The authors report no potential financial conflicts of interest.
Arch Intern Med. 2003;163:2469-2473
Learning Objectives Upon completion of this activity, participants will be able to:
Identify drug interactions that can increase the INR level in patients receiving warfarin. Compare the efficacy and safety of oral vs. intravenous phytonadione in the treatment of excess anticoagulation with warfarin.
Clinical Context According to the authors of the current study, excessive anticoagulation occurs in 0.2% to 0.3% of patients receiving long-term anticoagulation with warfarin. Physicians prescribing warfarin should be mindful of the multiple drug interactions that account for a significant number of patients with INR levels increased above treatment goals. A review of warfarin therapy by Horton and Bushwick, appearing in the Feb. 1, 1999, issue of American Family Physician, suggests that commonly used drugs such as thyroid replacement agents, trimethoprim-sulfamethoxazole, cimetidine, and metronidazole can raise the INR in patients receiving warfarin. Conversely, antibiotics such as dicloxacillin and nafcillin can reduce the INR in warfarin-treated patients.
To minimize the risk of bleeding, prompt recognition and treatment of patients with an INR elevated above 4.0 is critical. Physicians can withhold warfarin with or without administering phytonadione to help lower the INR to safe levels. Traditionally, phytonadione has been administered either intravenously or subcutaneously, but a prospective trial by Crowther and colleagues that appeared in the Aug. 20, 2002, issue of Annals of Internal Medicine showed that oral phytonadione restored INR to goal levels in 58% of patients with warfarin-induced hypocoagulability compared with 24% of subjects receiving subcutaneous phytonadione.
The Crowther study evaluated patients with a wide range of INR levels and treated all subjects with 1 mg of phytonadione (oral or subcutaneously). In the current study, Lubetsky and colleagues stratify warfarin-treated patients with elevated INR levels to different regimens of phytonadione, administered either orally or intravenously, to compare the efficacy and safety of these different routes of administration.
Study Highlights Study subjects were consecutive warfarin-treated patients at one institution presenting with an INR of 6.0 or higher. Patients were excluded if they had evidence of major bleeding, a history of thromboembolic phenomena during anticoagulant therapy, or liver or kidney disease.
Participants with INR values between 6 and 10 were randomized to receive phytonadione, either 0.5 mg intravenously or 2.5 mg orally. Those with an INR higher than 10 received phytonadione 1.0 mg intravenously or 5 mg orally.
The main study outcome was to reduce patients INR levels to between 2 and 4, defined as the safety zone for anticoagulant therapy. The authors investigated patients return to these levels at 6, 12, and 24 hours after phytonadione treatment, although INR levels were followed more frequently to define time-response to treatment. Subjects were also followed for major bleeding events, decline of INR levels to less than 2.0, and occurrence of thrombosis. Participants were followed for up to 28 days after hospitalization to monitor any late adverse events. During a 1-year period, 61 patients with 66 episodes of excessive anticoagulation were evaluated. 71% of these subjects had an INR between 6 and 10. Most participants were receiving warfarin for either an artificial valve or atrial fibrillation, and drug interactions accounted for 18 of the elevated INR levels. No cause was found for 27 episodes of excessive anticoagulation.
The INR declined more rapidly with intravenous compared with oral phytonadione in participants with an INR between 6 and 10. At 6 and 12 hours, significantly more subjects in the intravenous phytonadione group had reached their INR goal. However, at 24 hours, there was no difference between the 2 groups.
In subjects with an initial INR between 6 and 10 treated with intravenous phytonadione, mean INR values were 3.8 and 2.6 at 12 and 24 hours, respectively. Values in the same subgroup for those treated with oral phytandione therapy were 4.4 and 2.9, respectively, a nonsignificant difference from intravenous treatment. In patients with an initial INR level greater than 10, both intravenous and oral phytonadione rapidly reduced the INR. There was no difference between the 2 treatments in returning the INR to safe levels.
Overall, 6 subjects failed to return to safe INR levels. Failure rates were 4% in the group with INR levels between 6 and 10 and 21% in the group with an INR greater than 10. However, 5 of the 6 patients who did not reach safe levels had an improvement in their INR level at 24 hours to 4.1 to 4.6. There was no difference between oral and intravenous phytonadione therapy in treatment failure.
In participants with an initial INR level between 6 and 10, INR levels decreased below 2.0 in 7 patients treated with intravenous phytonadione compared with 2 subjects treated with oral phytandione. This difference did not achieve statistical significance.
All patients restarted warfarin treatment at 24 hours after phytonadione administration. 59 of 61 subjects were within the range of their INR goal at 72 hours.
There were no major bleeding events or adverse events reported during the study follow-up period.
Pearls for Practice Excessive anticoagulation is fairly common with warfarin therapy, and drug interactions account for a significant percentage of these complications.
Oral phytonadione is a reasonable option for patients with excessive anticoagulation secondary to warfarin therapy. Intravenous phytonadione should be used if it is critical to achieve lower INR levels within 12 hours.

Below is an informed consent that you can copy and use.

Vitamin K Informed Consent and Waiver

Vitamin K injections are routinely given to newborns when they are born in the hospital, to prevent vitamin K deficiency bleeding (VKDB). VKDB presents in three different ways:
• Early VKDB, occurring on the first day of life, is rare and confined to infants born to mothers who have received medications that interfere with vitamin K metabolism. These include the anticonvulsants phenytoin, barbiturates or carbamazepam, the antitubercular drugs rifampicin or isoniazid and the vitamin K antagonists warfarin and phenprocoumarin. The reported incidence in infants of mothers who have received such medications without vitamin K supplementation is between 6 and 12 per cent
Classical VKDB occurs from one to seven days after birth and is more common in infants who are unwell at birth or who have delayed onset of feeding. Bleeding is usually from the umbilicus, gastrointestinal tract, skin punctures, surgical sites and uncommonly in the brain. Severe intracranial hemorrhage may occur suddenly and result in death or severe CNS dysfunction. The incidence reported in the literature is variable, with rates of 0.25 to 1.5 per cent in early reports of both sick and well infants to 0 to 0.44 per cent in recent reviews predominantly of well infants. There is considerable uncertainty about the true rates of classical VKDB since full diagnostic criteria outlined above were seldom met.
• Late VKDB occurs from eight days to six months after birth, with most presenting at one to three months. It is almost completely confined to fully breast-fed infants. Several recent reports emphasize a late form of hemorrhagic disease occurring at 4-6 weeks of age, often manifest as intracranial bleeding, and occurring exclusively in breast-fed infants who did not receive vitamin K as newborns or have fat malabsorption. Other sites of bleeding include skin, gastrointestinal tract, umbilicus or surgical sites. About 30 per cent have minor bruising or other signs of coagulopathy (warning bleeds), preceding the serious hemorrhage. Infants at risk may have signs of predisposing cholestatic liver disease such as prolonged jaundice, pale stools, and hepatosplenomegaly. The rate of VKDB in infants who did not receive vitamin K at birth has been reported as between five and 20 per 100,000 births. The mortality is about 30 per cent (Loughnan and McDougall 1993).
Not all parents are comfortable with having their newborns injected with vitamin K. This document tells you the reasons vitamin K is routinely given to all newborns born in hospital. The disorders above are almost completely preventable if the vitamin K injection is given at birth.
Your midwife can provide a form of oral vitamin K. K-Quinone-is an oil soluble source of vitamin K-1 (phytonadione), the non-toxic natural form of vitamin K present in plants. K-Quinoe is extracted from alfalfa, nettles and green tea. Each drop provides 2 mg of vitamin K-1 activity. This particular product has not been studied by the medical community and may provide some degree of protection against VKDB, although it will probably not be effective against vitamin K deficiency caused by a babys inability to metabolize fats. The vitamin K is given at birth, at one to two weeks of age, and at six weeks of age.
The mother can purchase this vitamin K when she orders her birth kit and take it herself if she wants to increase vitamin K levels in her breastmilk. Mothers given oral supplements of 0.5 - 3.omg vitamin K per day produce substantially increased breast milk vitamin K levels.
If you do not want your baby to receive vitamin K please sign and date below. If you want your baby to receive injectable vitamin K you must arrange with a doctor to have the vitamin K injection present at the birth, or to have your baby seen by the doctor in the babys first week of life, and given the injection at the physicians office.
If you want to use oral vitamin K, please tell your midwife.
- - - - - - - - - - - - - - - - - - -- - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - -
I/we refuse to give vitamin K to our new baby. I/we have read the preceding information and understand this could result in serious injury or even death.
_________________________________________ _________________
Parents signatures
Date
I/we agree to have the vitamin K injection and will arrange for a doctor to do this.
_________________________________________ _________________
Parents signatures
Date
I/We have decided to use oral vitamin K for our baby. We agree to be sure that all three doses are administered at the appropriate intervals of birth, one to two weeks, and at six weeks.
_________________________________________ _________________ Parents signatures
Date